vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and OXFORD INDUSTRIES INC (OXM). Click either name above to swap in a different company.
OXFORD INDUSTRIES INC is the larger business by last-quarter revenue ($307.3M vs $183.1M, roughly 1.7× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -20.7%, a 34.1% gap on every dollar of revenue. On growth, OXFORD INDUSTRIES INC posted the faster year-over-year revenue change (-0.2% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-47.9M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -3.0%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Oxford Industries, Inc. is a publicly traded clothing company in the United States that specializes in high-end clothing and apparel. The company carries many major labels, including Tommy Bahama, Lilly Pulitzer, Johnny Was and Southern Tide.
AMPH vs OXM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $307.3M |
| Net Profit | $24.4M | $-63.7M |
| Gross Margin | 46.8% | 60.3% |
| Operating Margin | 19.4% | -27.7% |
| Net Margin | 13.3% | -20.7% |
| Revenue YoY | -1.8% | -0.2% |
| Net Profit YoY | -35.7% | -1517.6% |
| EPS (diluted) | $0.51 | $-4.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $307.3M | ||
| Q3 25 | $191.8M | $403.1M | ||
| Q2 25 | $174.4M | $392.9M | ||
| Q1 25 | $170.5M | — | ||
| Q4 24 | $186.5M | $308.0M | ||
| Q3 24 | $191.2M | $419.9M | ||
| Q2 24 | $182.4M | $398.2M | ||
| Q1 24 | $171.8M | $404.4M |
| Q4 25 | $24.4M | $-63.7M | ||
| Q3 25 | $17.4M | $16.7M | ||
| Q2 25 | $31.0M | $26.2M | ||
| Q1 25 | $25.3M | — | ||
| Q4 24 | $38.0M | $-3.9M | ||
| Q3 24 | $40.4M | $40.6M | ||
| Q2 24 | $37.9M | $38.4M | ||
| Q1 24 | $43.2M | $-60.1M |
| Q4 25 | 46.8% | 60.3% | ||
| Q3 25 | 51.4% | 61.4% | ||
| Q2 25 | 49.6% | 64.2% | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | 63.1% | ||
| Q3 24 | 53.3% | 63.1% | ||
| Q2 24 | 52.2% | 64.9% | ||
| Q1 24 | 52.4% | 60.9% |
| Q4 25 | 19.4% | -27.7% | ||
| Q3 25 | 13.2% | 6.3% | ||
| Q2 25 | 24.2% | 9.2% | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 24.2% | -2.0% | ||
| Q3 24 | 29.8% | 12.5% | ||
| Q2 24 | 30.3% | 13.2% | ||
| Q1 24 | 27.9% | -20.1% |
| Q4 25 | 13.3% | -20.7% | ||
| Q3 25 | 9.0% | 4.1% | ||
| Q2 25 | 17.8% | 6.7% | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 20.4% | -1.3% | ||
| Q3 24 | 21.1% | 9.7% | ||
| Q2 24 | 20.8% | 9.6% | ||
| Q1 24 | 25.1% | -14.9% |
| Q4 25 | $0.51 | $-4.28 | ||
| Q3 25 | $0.37 | $1.12 | ||
| Q2 25 | $0.64 | $1.70 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | $-0.25 | ||
| Q3 24 | $0.78 | $2.57 | ||
| Q2 24 | $0.73 | $2.42 | ||
| Q1 24 | $0.81 | $-3.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $8.0M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $528.0M |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $8.0M | ||
| Q3 25 | $276.2M | $6.9M | ||
| Q2 25 | $231.8M | $8.2M | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | $7.0M | ||
| Q3 24 | $250.5M | $18.4M | ||
| Q2 24 | $217.8M | $7.7M | ||
| Q1 24 | $289.6M | $7.6M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $29.0M |
| Q4 25 | $788.8M | $528.0M | ||
| Q3 25 | $776.7M | $597.1M | ||
| Q2 25 | $757.5M | $592.4M | ||
| Q1 25 | $751.3M | — | ||
| Q4 24 | $732.3M | $612.2M | ||
| Q3 24 | $727.7M | $621.6M | ||
| Q2 24 | $713.3M | $592.9M | ||
| Q1 24 | $672.4M | $560.9M |
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B | ||
| Q1 24 | $1.6B | $1.1B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.05× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-9.1M |
| Free Cash FlowOCF − Capex | $24.6M | $-47.9M |
| FCF MarginFCF / Revenue | 13.4% | -15.6% |
| Capex IntensityCapex / Revenue | 4.5% | 12.6% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-79.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-9.1M | ||
| Q3 25 | $52.6M | $83.5M | ||
| Q2 25 | $35.6M | $-3.9M | ||
| Q1 25 | $35.1M | — | ||
| Q4 24 | $29.0M | $-18.2M | ||
| Q3 24 | $60.0M | $88.8M | ||
| Q2 24 | $69.1M | $32.9M | ||
| Q1 24 | $55.3M | $74.9M |
| Q4 25 | $24.6M | $-47.9M | ||
| Q3 25 | $47.2M | $52.3M | ||
| Q2 25 | $25.0M | $-27.4M | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | $-56.9M | ||
| Q3 24 | $46.2M | $47.2M | ||
| Q2 24 | $63.1M | $21.0M | ||
| Q1 24 | $46.5M | $55.3M |
| Q4 25 | 13.4% | -15.6% | ||
| Q3 25 | 24.6% | 13.0% | ||
| Q2 25 | 14.3% | -7.0% | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | -18.5% | ||
| Q3 24 | 24.1% | 11.2% | ||
| Q2 24 | 34.6% | 5.3% | ||
| Q1 24 | 27.1% | 13.7% |
| Q4 25 | 4.5% | 12.6% | ||
| Q3 25 | 2.8% | 7.7% | ||
| Q2 25 | 6.1% | 6.0% | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | 12.6% | ||
| Q3 24 | 7.2% | 9.9% | ||
| Q2 24 | 3.3% | 3.0% | ||
| Q1 24 | 5.1% | 4.8% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 5.00× | ||
| Q2 25 | 1.15× | -0.15× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 2.19× | ||
| Q2 24 | 1.82× | 0.86× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
OXM
| Sales Channel Retail | $162.9M | 53% |
| Sales Channel Wholesale | $61.3M | 20% |
| Johnny Was | $45.4M | 15% |
| Sales Channel Food And Beverage | $29.3M | 10% |
| Other Foreign Countries | $9.0M | 3% |
